{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:17:38Z","timestamp":1782947858732,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K18666"],"award-info":[{"award-number":["JP25K18666"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cytochrome P450 3A (CYP3A) enzymes metabolize many clinically important drugs. Previously, we clarified that bardoxolone methyl (BX), an Nrf2 activator, decreased CYP3A mRNA expression level in HepG2 cells. However, its effects on hepatic CYP3A protein and\n                    <jats:italic>in vivo<\/jats:italic>\n                    drug disposition remained unclear. This study investigated whether BX downregulates hepatic CYP3A expression and activity, and determine its impact on the pharmacokinetics of midazolam (MDZ), involving atypical substrate probing for CYP3A, in rats.\u3000Male Sprague-Dawley rats received a single intraperitoneal dose of BX (10\u00a0mg\/kg). BX decreased hepatic CYP3A mRNA and protein levels, and V\n                    <jats:sub>max<\/jats:sub>\n                    value for MDZ hydroxylation without altering the K\n                    <jats:sub>m<\/jats:sub>\n                    value. Intravenous MDZ pharmacokinetics (5\u00a0mg\/kg) were unaffected following BX treatment; however, oral administration (15\u00a0mg\/kg) showed reduced apparent clearance (CL\n                    <jats:sub>tot<\/jats:sub>\n                    \/F), a measure of inherent\n                    <jats:italic>in vivo<\/jats:italic>\n                    metabolic capacity, leading to increases in AUC and bioavailability. No significant alterations in liver weight or plasma hepatic markers were observed. In conclusion, we suggest that hepatic CYP3A expression and intrinsic metabolic capacity are suppressed by BX, thereby markedly increasing the oral bioavailability of CYP3A substrates. These findings may help in the early detection of clinically significant drug interactions between Nrf2 activators and CYP3A substrate drugs.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-50118-9","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:55:42Z","timestamp":1777359342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Downregulation of hepatic CYP3A isoforms by bardoxolone methyl in rats and its impact on in vivo metabolic capacity reflecting pharmacokinetics"],"prefix":"10.1038","volume":"16","author":[{"given":"Yuichiro","family":"Hori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Fukuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Shirane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyotaro","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhito","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"50118_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112686","volume":"10","author":"LS Klyushova","year":"2022","unstructured":"Klyushova, L. S., Perepechaeva, M. L. & Grishanova, A. Y. The role of CYP3A in health and disease. Biomedicines 10, 2686. https:\/\/doi.org\/10.3390\/biomedicines10112686 (2022).","journal-title":"Biomedicines"},{"key":"50118_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103\u2013141 (2013).","journal-title":"Pharmacol. Ther."},{"key":"50118_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1124\/dmd.109.028290","volume":"38","author":"X Zhang","year":"2010","unstructured":"Zhang, X. et al. Inhibition of CYP3A by erythromycin: In vitro-in vivo correlation in rats. Drug Metab. Dispos. 38, 61\u201372 (2010).","journal-title":"Drug Metab. Dispos."},{"key":"50118_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00228-012-1403-6","volume":"69","author":"M Hoch","year":"2013","unstructured":"Hoch, M., Hoever, P., Alessi, F., Theodor, R. & Dingermanse, J. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects. Eur. J. Clin. Pharmacol. 69, 523\u2013532 (2013).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"50118_CR5","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1124\/dmd.31.7.938","volume":"31","author":"KC Patki","year":"2003","unstructured":"Patki, K. C., Von Moltke, L. L. & Greenblatt, D. J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: Role of CYP3A4 and CYP3A5. Drug Metab. Dispos. 31, 938\u2013944 (2003).","journal-title":"Drug Metab. Dispos."},{"key":"50118_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/0049825021000012655","volume":"32","author":"SL Eeckhoudt","year":"2002","unstructured":"Eeckhoudt, S. L., Horsmans, Y. & Verbeeck, R. K. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 32, 975\u2013984 (2002).","journal-title":"Xenobiotica"},{"key":"50118_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/00498250701245250","volume":"37","author":"JP Chovan","year":"2007","unstructured":"Chovan, J. P., Ring, S. C., Yu, E. & Baldino, J. P. Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats. Xenobiotica 37, 459\u2013473 (2007).","journal-title":"Xenobiotica"},{"key":"50118_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","volume":"59","author":"KE Thummel","year":"1996","unstructured":"Thummel, K. E. et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59, 491\u2013502 (1996).","journal-title":"Clin. Pharmacol. Ther."},{"key":"50118_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/138920008784220664","volume":"9","author":"SF Zhou","year":"2008","unstructured":"Zhou, S. F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 9, 310\u2013322 (2008).","journal-title":"Curr. Drug Metab."},{"key":"50118_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser, G. K., Spence, J. D. & Bailey, D. G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38, 41\u201357 (2000).","journal-title":"Clin. Pharmacokinet."},{"key":"50118_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111286","volume":"9","author":"A Novotn\u00e1","year":"2014","unstructured":"Novotn\u00e1, A. et al. Dual effects of ketoconazole cis-enantiomers on CYP3A4 in human hepatocytes and HepG2 cells. PLoS One 9, e111286. https:\/\/doi.org\/10.1371\/journal.pone.0111286 (2014).","journal-title":"PLoS One"},{"key":"50118_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1124\/dmd.120.000124","volume":"49","author":"H Takano","year":"2021","unstructured":"Takano, H. et al. Downregulation of CYP1A2, CYP2B6, and CYP3A4 in human hepatocytes by prolyl hydroxylase domain 2 inhibitors via hypoxia-inducible factor\u2011\u03b1 stabilization. Drug Metab. Dispos. 49, 20\u201330 (2021).","journal-title":"Drug Metab. Dispos."},{"key":"50118_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1159\/000327599","volume":"33","author":"PE Pergola","year":"2011","unstructured":"Pergola, P. E. et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b\u20134 CKD. Am. J. Nephrol. 33, 469\u2013476 (2011).","journal-title":"Am. J. Nephrol."},{"key":"50118_CR14","doi-asserted-by":"publisher","first-page":"10370","DOI":"10.18632\/aging.103263","volume":"12","author":"JL Yang","year":"2020","unstructured":"Yang, J. L. et al. Keap1\u2013Nrf2 signaling activation by bardoxolone methyl ameliorates high glucose-induced oxidative injury in human umbilical vein endothelial cells. Aging (Albany NY) 12, 10370\u201310380 (2020).","journal-title":"Aging (Albany NY)"},{"key":"50118_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1055\/a-2111-6649","volume":"73","author":"K Nagai","year":"2023","unstructured":"Nagai, K. et al. Altered gene expression of cytochrome P450 and ABC transporter in human hepatocellular carcinoma HepG2 cells exposed to bardoxolone methyl. Drug Res. (Stuttg) 73, 473\u2013475 (2023).","journal-title":"Drug Res. (Stuttg)"},{"key":"50118_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00068-019-01216-z","volume":"47","author":"E Kad\u0131o\u011flu","year":"2021","unstructured":"Kad\u0131o\u011flu, E., Tek\u015fen, Y., Ko\u00e7ak, C. & Ko\u00e7ak, F. E. Beneficial effects of bardoxolone methyl, an Nrf2 activator, on crush-related acute kidney injury in rats. Eur. J. Trauma Emerg. Surg. 47, 241\u2013250 (2021).","journal-title":"Eur. J. Trauma Emerg. Surg."},{"key":"50118_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein\u2013dye binding. Anal. Biochem. 72, 248\u2013254 (1976).","journal-title":"Anal. Biochem."},{"key":"50118_CR18","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1124\/jpet.102.035972","volume":"302","author":"T Kotegawa","year":"2002","unstructured":"Kotegawa, T. et al. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J. Pharmacol. Exp. Ther. 302, 1228\u20131237 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"50118_CR19","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1080\/00498254.2019.1578004","volume":"49","author":"S Fukuno","year":"2019","unstructured":"Fukuno, S. et al. Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5\u2011fluorouracil: Relevance to pharmacokinetics of midazolam. Xenobiotica 49, 1470\u20131477 (2019).","journal-title":"Xenobiotica"},{"key":"50118_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1358\/mf.2007.29.1.1074690","volume":"29","author":"T Elkiran","year":"2007","unstructured":"Elkiran, T. et al. Differential alteration of drug-metabolizing enzyme activities after cyclophosphamide\/adriamycin administration in breast cancer patients. Methods Find. Exp. Clin. Pharmacol. 29, 27\u201332 (2007).","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"50118_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/bdd.1930","volume":"36","author":"K Nagai","year":"2015","unstructured":"Nagai, K. et al. Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol. Biopharm. Drug Dispos. 36, 174\u2013182 (2015).","journal-title":"Biopharm. Drug Dispos."},{"key":"50118_CR22","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-11-2703","volume":"18","author":"DS Hong","year":"2012","unstructured":"Hong, D. S. et al. A phase I first\u2011in\u2011human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. 18, 3396\u20133406 (2012).","journal-title":"Clin. Cancer Res."},{"key":"50118_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/5693732","volume":"2023","author":"A Huang","year":"2023","unstructured":"Huang, A. et al. Bardoxolone methyl ameliorates myocardial ischemia\/reperfusion injury by activating the Nrf2\/HO-1 signaling pathway. Cardiovasc. Ther. 2023, 5693732. https:\/\/doi.org\/10.1155\/2023\/5693732 (2023).","journal-title":"Cardiovasc. Ther."},{"key":"50118_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.46.120604.141046","volume":"47","author":"TW Kensler","year":"2007","unstructured":"Kensler, T. W., Wakabayashi, N. & Biswal, S. Cell survival responses to environmental stresses via the Keap1\u2013Nrf2\u2013ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89\u2013116 (2007).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"50118_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1211\/0022357991771971","volume":"51","author":"F Higashikawa","year":"1999","unstructured":"Higashikawa, F., Murakami, T., Kaneda, T., Kato, A. & Takano, M. Dose\u2011dependent intestinal and hepatic first\u2011pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. J. Pharm. Pharmacol. 51, 67\u201372 (1999).","journal-title":"J. Pharm. Pharmacol."},{"key":"50118_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1023\/A:1023433502647","volume":"20","author":"S Tolle-Sander","year":"2003","unstructured":"Tolle-Sander, S. et al. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm. Res. 20, 757\u201364 (2003).","journal-title":"Pharm. Res."},{"key":"50118_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1124\/jpet.102.044719","volume":"305","author":"CL Cummins","year":"2003","unstructured":"Cummins, C. L., Salphati, L., Reid, M. J. & Benet, L. Z. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: Studies using the rat single-pass intestinal perfusion model. J. Pharmacol. Exp. Ther. 305, 306\u2013314 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"50118_CR28","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1053\/j.ajkd.2004.09.004","volume":"45","author":"EL Swart","year":"2005","unstructured":"Swart, E. L. et al. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. Am. J. Kidney Dis. 45, 360\u2013371 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"50118_CR29","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1248\/bpb.26.510","volume":"26","author":"T Usui","year":"2003","unstructured":"Usui, T., Saitoh, Y. & Komada, F. Induction of CYP3As in HepG2 cells by several drugs: Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol. Pharm. Bull. 26, 510\u2013517 (2003).","journal-title":"Biol. Pharm. Bull."},{"key":"50118_CR30","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1158\/1078-0432.CCR-06-0023","volume":"12","author":"KA Charles","year":"2006","unstructured":"Charles, K. A. et al. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin. Cancer Res. 12, 7492\u20137497 (2006).","journal-title":"Clin. Cancer Res."},{"key":"50118_CR31","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1124\/dmd.112.045245","volume":"40","author":"TJ Velenosi","year":"2012","unstructured":"Velenosi, T. J. et al. Down-regulation of hepatic CYP3A and CYP2C-mediated metabolism in rats with moderate chronic kidney disease. Drug Metab. Dispos. 40, 1508\u20131514 (2012).","journal-title":"Drug Metab. Dispos."},{"key":"50118_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0221-6","volume":"19","author":"H Molanaei","year":"2018","unstructured":"Molanaei, H. et al. Inflammation down-regulates CYP3A4\u2011catalysed drug metabolism in hemodialysis patients. BMC Pharmacol. Toxicol. 19, 33. https:\/\/doi.org\/10.1186\/s40360-018-0221-6 (2018).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"50118_CR33","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1111\/j.1476-5381.2012.01933.x","volume":"166","author":"AS Gandhi","year":"2012","unstructured":"Gandhi, A. S. et al. CYP3A\u2011dependent drug metabolism is reduced in bacterial inflammation in mice. Br. J. Pharmacol. 166, 2176\u20132187 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"50118_CR34","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1124\/dmd.120.000010","volume":"48","author":"T Ashino","year":"2020","unstructured":"Ashino, T., Yamamoto, M. & Numazawa, S. Nrf2 antioxidative system is involved in cytochrome P450 gene expression and activity: A delay in pentobarbital metabolism in Nrf2-deficient mice. Drug Metab. Dispos. 48, 673\u2013680 (2020).","journal-title":"Drug Metab. Dispos."},{"key":"50118_CR35","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1517\/17425255.2.6.875","volume":"2","author":"M Martignoni","year":"2006","unstructured":"Martignoni, M., Groothuis, G. M. M. & de Kanter, R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert. Opin. Drug Metab. Toxicol. 2, 875\u2013894 (2006).","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"50118_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.taap.2012.10.029","volume":"266","author":"EJ Poulton","year":"2013","unstructured":"Poulton, E. J. et al. Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. Toxicol. Appl. Pharmacol. 266, 122\u2013131 (2013).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"50118_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.540","volume":"7","author":"J Aubets","year":"2019","unstructured":"Aubets, J. et al. No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P\u2011glycoprotein (P\u2011gp) drug transporter. Pharmacol. Res. Perspect. 7, e00540. https:\/\/doi.org\/10.1002\/prp2.540 (2019).","journal-title":"Pharmacol. Res. Perspect."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50118-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:42:40Z","timestamp":1782945760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50118-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50118"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50118-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20178"}}